CORDIS
EU research results

CORDIS

English EN

Affording Recovery In Stroke

Objective

Stroke poses a massive clinical, social and economic burden, yet we have very limited effective therapies. This inadequacy is in spite of intensive research efforts and numerous failed clinical trials. Leading European stroke researchers and clinicians with a track record of established cooperation will share their complementary expertise, and team up with SME partners with high profile R&D and ongoing, promising clinical trials. Based on a thorough reexamination of the failures and bottlenecks of previous attempts to develop effective therapies for stroke, the ARISE consortium proposes an integrative and innovative approach to overcome the translational roadblock. ARISE research will result in a number of novel, promising therapies, including safer thrombolytics, modulators of the immune system and inflammation, compounds inducing or mimicking endogenous neuroprotection, therapies to induce repair of lost function, as well as a fast way to selectively cool the brain. We will work on a common model and methods platform, in which for the first time relevant comorbidities, gender, age, and long term outcomes will be investigated. Training of young researchers will lead to a standardisation and harmonisation of laboratory practices within the consortium, and implement the standard operating procedures generated by the consortium. Importantly, the ARISE consortium combines expertise in clinical as well as preclinical stroke research. To obtain clinical proof of principle and to translate our findings into effective therapy of stroke, ARISE is conducting clinical trials and has established a dedicated clinical platform to (1) provide advice to the basic researchers of the consortium with regard to clinically relevant questions and modelling, (2) to periodically review the ongoing development of innovative therapies, and to (3) ultimately take the most promising preclinical strategy developed by the ARISE consortium into a multicenter randomized clinical trial.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Address

Chariteplatz 1
10117 Berlin

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 178 932

Administrative Contact

Eveline Fräßdorf (Ms.)

Participants (16)

Sort alphabetically

Sort by EU Contribution

Expand all

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 744 675

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 1 229 189

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 783 133

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 745 590

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 856 568

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 1 068 362

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 587 296

INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK

Poland

EU Contribution

€ 549 568

UNIVERSITEIT GENT

Belgium

EU Contribution

€ 517 696

QUICK COOL AB

Sweden

EU Contribution

€ 318 296

PAION DEUTSCHLAND GMBH

Germany

EU Contribution

€ 122 721

SYGNIS BIOSCIENCE GMBH & CO. KG

Germany

EU Contribution

€ 275 653

NSGENE AS

Denmark

EU Contribution

€ 92 423

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 505 500

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 351 944

UNIVERSITAT ZU LUBECK

Germany

EU Contribution

€ 319 230

Project information

Grant agreement ID: 201024

Status

Closed project

  • Start date

    1 March 2008

  • End date

    31 August 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 16 246 309,14

  • EU contribution

    € 11 246 776

Coordinated by:

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany